DexCom delivered a strong Q3 2025 with revenue of $1.21 billion, representing 22% reported growth and 20% organic growth, driven by robust performance in both U.S. and international markets. U.S. revenue grew 21% to $852 million, fueled by expanded Type 2 coverage and primary care penetration, while international revenue increased 22% to $357.4 million. The company achieved record EPS of $0.61, though gross margins dipped to 61.3% due to manufacturing scrap rates and expedited freight costs. Management raised full-year revenue guidance to $4.63B-$4.65B (approx. 15% growth) but lowered gross margin guidance to approximately 61% to account for ongoing supply chain fixes. Strategic highlights include the imminent broad launch of the G7 15-day sensor with secured reimbursement, Stelo surpassing $100 million in revenue in its first year, and the regulatory submission of the DexCom Smart Basal software.
| Metric | Value | Change |
|---|---|---|
| Q3 Revenue | $1.21 Billion | +22% Reported / +20% Organic |
| U.S. Revenue | $852 Million | +21% |
| International Revenue | $357.4 Million | +22% Reported / +18% Organic |
| EPS | $0.61 | Record High |
| Gross Margin | 61.3% | -170 bps YoY |
| Operating Margin | 22.6% | +130 bps YoY |
| Cash & Equivalents | >$3.3 Billion | Strong |
DexCom is aggressively targeting the massive Type 2 non-insulin (NIT) market, having secured coverage for 6 million lives with a goal of reaching 25 million. Management highlighted that 'access expansion is a matter of when, not if,' supported by a growing body of evidence including randomized controlled trial (RCT) data readouts expected early next year. This strategic focus on primary care and basal insulin populations diversifies revenue beyond the saturated Type 1 intensive market.
The company is preparing for the broad launch of its G7 15-day system, having finalized contracts with Medicare and major commercial payers to ensure reimbursement at the same net price. This launch is critical for 2026 growth, with management noting it will allow them to 'go after additional patients' and improve gross margins over time by reducing the frequency of sensor shipments.
The Stelo product line has validated the Over-the-Counter (OTC) metabolic health strategy, surpassing $100 million in revenue in just 12 months. Management plans to expand Stelo internationally and is enhancing the app with a consumer-focused experience, signaling a successful adjacency to the core prescription business.
Innovation in software is becoming a key differentiator, specifically the DexCom Smart Basal feature currently under FDA review. This algorithm aims to automate insulin titration, addressing a major barrier for basal insulin users and potentially driving adherence and market share in the basal population.
International growth is accelerating, marking the third straight quarter of improvement, driven by recent coverage expansions in markets like France and Canada. Management noted that France has become one of the fastest-growing markets, demonstrating the success of the DexCom ONE+ strategy in securing formulary access.
Gross margin pressure remains a significant concern, contracting to 61.3% from 63.0% in the prior year. Management attributed this to higher scrap rates from third-party component issues and expedited freight costs. While they expect these to dissipate in Q4 and 2026, the full-year gross margin guidance was lowered to approximately 61%.
Management acknowledged 'noise' and 'deployment challenges' with the G7 sensor that led to out-of-box failures earlier in the year. While they claim the issues are resolved, CFO Jereme Sylvain admitted there was 'likely been a bit of an impact on new starts here over the course of the third quarter,' resulting in slightly below record new patient additions.
The company provided a conservative outlook for 2026, stating that the top end of their internal growth range is 'slightly below where the Street is.' This suggests that the easy growth from initial Type 2 coverage expansions may be slowing or that the mix shift to lower-acuity patients is impacting revenue per patient faster than anticipated.
There is a persistent gap between unit volume growth and revenue growth due to channel mix shifts (pharmacy vs. DME) and pricing dynamics. While management noted the gap is narrowing, the implied Q4 growth on a two-year stack basis suggests a deceleration trend that analysts questioned repeatedly.
Overall: Management conveyed a tone of resilience and confidence, acknowledging recent operational 'noise' regarding product quality but emphasizing that issues have been identified and resolved. Jake Leach was assertive regarding the company's commitment to quality and customer experience, while Jereme Sylvain remained prudent and transparent regarding financial headwinds and conservative 2026 expectations.
Confidence: HIGH - Management demonstrated high confidence through the raising of revenue guidance and emphasis on record EPS. They were specific about the root causes of margin pressure (scrap/freight) and detailed the corrective actions, suggesting strong control over operations despite temporary setbacks.
$4.630 Billion - $4.650 Billion (approx. 15% growth)
Approximately 61%
20% - 21%
29% - 30%
Hedging & Uncertainty: Management employed careful hedging regarding the 2026 outlook, frequently using the phrase 'base case' to describe their guidance. Jacob Leach stated the top end of their range is 'probably slightly below where the Street is,' effectively lowering expectations without providing specific numbers. They also hedged on the timing of new Type 2 coverage, stating it is a 'matter of when, not if,' but acknowledging 'timing is hard to predict.' This language suggests a desire to under-promise to ensure delivery, particularly after recent operational stumbles.
The top end of that range is probably slightly below where the Street is. - Jacob Leach, President and Interim CEO
The customer is and will always be the North Star for this company. - Jacob Leach
There's likely been a bit of an impact on new starts here over the course of the third quarter. - Jereme Sylvain, CFO
Our base case won't include those [coverage wins]. - Jereme Sylvain
We expect these scrap rates to continue to improve in the coming months. - Jereme Sylvain
I'm confident to say that the quality of the sensors coming off our lines today is exceptional. - Jacob Leach
Analyst Sentiment: Analysts were highly focused on the 'noise' surrounding G7 quality and the conservative framing of 2026 growth. There was skepticism regarding the deceleration of growth on a two-year stack basis and the persistence of gross margin headwinds.
Management Responses: Management was defensive but detailed regarding quality issues, explaining the specific 'deployment' problems and asserting that sensors currently being produced are of exceptional quality. They stood firm on the 2026 'base case' guidance, refusing to incorporate potential coverage wins into the base numbers to avoid missing expectations.
Detailed discussion on G7 'deployment' failures and out-of-box complaints, with management asserting these issues have been resolved in the factory.
Framing of 2026 guidance, with management clarifying that their 'base case' excludes potential new coverage wins and is slightly below current Street estimates.
Gross margin specifics, with CFO Jereme Sylvain breaking down the impact as '50-50' between scrap rates and expedited freight costs.
Stelo performance and its $100M revenue milestone, confirming the product's viability in the consumer market.
Patient utilization rates across different cohorts (Type 1 vs Type 2), with non-insulin utilization around 75%.
DexCom remains a core holding in the diabetes space, executing with 20% organic growth and record EPS despite temporary headwinds. The company is successfully navigating the transition to a broader Type 2 patient base and launching high-impact innovations like the G7 15-day sensor and Stelo. While management's conservative 2026 commentary and gross margin pressure create near-term volatility, the fundamental drivers—specifically the massive under-penetrated Type 2 market and secured reimbursement for new products—support a positive long-term thesis. The resolution of manufacturing scrap issues and the shift back to ocean freight in Q4 should set up margin expansion for 2026.
Management noted 'positive updates to the latest standards of care' for Type 2 patients, indicating a favorable macro trend for coverage expansion. They expect randomized controlled trial (RCT) data in early 2026 to further drive this advocacy.
International growth accelerated for the third straight quarter (18% organic), with specific strength in France and Canada following recent coverage expansions, suggesting global markets are replicating U.S. access success.
The company faced headwinds from expedited freight costs but has begun transitioning back to ocean freight, signaling a normalization of global logistics and a reduction in input costs moving forward.